3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
26
Magnetic Resonance Spectroscopy
14
Nivolumab
13
Docetaxel
13
Specimen Handling
11
Radiotherapy
9
Paclitaxel
9
Radiosurgery
8
Early Intervention, Educational
8
Cyclophosphamide
8
Gemcitabine
7
atezolizumab
6
Taxes
6
Surveys and Questionnaires
6
Standard of Care
6
Psychiatric Rehabilitation
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Pemetrexed
5
Methods
5
motexafin gadolinium
4
fludarabine
4
X-Rays
4
Interviews as Topic
4
Immunoglobulin G
4
Fluorouracil
4
Educational Status
4
Cisplatin
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Genitourinary
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled